Hoag Family Cancer Institute and Pickup Family Neurosciences Institute at Hoag, in collaboration with Nascent Biotech, Inc announced today a first in the nation clinical trial for a novel immunotherapy treatment that holds considerable promise for glioblastoma (GBM), the deadliest form of brain cancer. Testing Pritumumab, a unique monoclonal antibody that attacks cancers originating in the cells lining an organ—referred to as epithelial cells, targeted cancers include cancers of the brain, breast, colon and pancreas as well as melanoma. Prior Phase I and II clinical trials in Japan focused on the treatment of high-grade gliomas including GBM. Hoag Hospital lands on TrialSite News’ SiteWatch Leading.
The Study at Hoag’s Neuro-Oncology
The Phase I clinical trial leverages the Hoag Family Cancer Institute and Pickup Family Neurosciences Institute’s assets in their collaboration when treating all aspects of brain tumors. With more than 20,000 new cases of GBM diagnosed in the U.S. every year, Hoag’s infrastructure in its Center for Research Education, as well as Hoag’s neurosciences and cancer expertise and reputation appealed to Nascent Biotech as they chose a national site. Th...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).